NASDAQ:GRFSGRIFOLS S A/S Stock Price, Forecast & News

GRIFOLS S A/S's stock was trading at $20.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GRFS shares have decreased by 8.5% and is now trading at $18.62. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GRIFOLS S A/S.

GRIFOLS S A/S is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for GRIFOLS S A/S.

GRIFOLS S A/S (NASDAQ:GRFS) released its earnings results on Tuesday, April, 21st. The biotechnology company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.24 by $0.01. The biotechnology company earned $1.43 billion during the quarter, compared to the consensus estimate of $1.40 billion. GRIFOLS S A/S had a return on equity of 11.92% and a net margin of 13.31%. View GRIFOLS S A/S's earnings history.

GRIFOLS S A/S declared a semi-annual dividend on Thursday, October 31st. Shareholders of record on Tuesday, December 3rd will be paid a dividend of $0.169 per share on Wednesday, December 11th. This represents a yield of 1.3%. The ex-dividend date of this dividend is Monday, December 2nd. This is a boost from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's dividend history.

GRIFOLS S A/S's stock split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were issued to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

News headlines about GRFS stock have been trending negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GRIFOLS S A/S earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about GRIFOLS S A/S.

GRIFOLS S A/S saw a increase in short interest in June. As of June 30th, there was short interest totaling 2,860,000 shares, an increase of 14.4% from the June 15th total of 2,500,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is presently 2.8 days. Currently, 1.1% of the company's stock are short sold. View GRIFOLS S A/S's Current Options Chain.

Some companies that are related to GRIFOLS S A/S include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Beigene (BGNE), GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA) and Catalent (CTLT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Allergan (AGN), Nektar Therapeutics (NKTR) and Johnson & Johnson (JNJ).

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

GRIFOLS S A/S's stock is owned by many different retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.13%).

GRFS stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc..

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GRFS stock can currently be purchased for approximately $18.62.

GRIFOLS S A/S has a market capitalization of $12.80 billion and generates $5.71 billion in revenue each year. The biotechnology company earns $700.16 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 22,244 workers across the globe.

The official website for GRIFOLS S A/S is www.grifols.com.

GRIFOLS S A/S's mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-0000 or via email at [email protected]